Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for Weil's disease has been reported in the published literature.
Research Landscape
Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.
12 clinical trials registered, 4 recruiting. Interventions under study include other interventions, drug therapy, medical devices, and procedural interventions. Pipeline includes 1 PHASE4, 1 PHASE2, 5 NA. Research is sponsored by a mix of industry and academic institutions.
Diseases are connected by shared genes, phenotypes, therapeutic targets, and MONDO disease hierarchy. The Rare badge reflects Kisho's rarity classification — scored from authoritative sources including OMIM, Orphanet, orphan drug designations, clinical trial activity, and published prevalence data.
→Are any of the 12 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?
FAQ
Frequently Asked Questions
Common questions about Weil's disease
Weil's disease is a form of severe leptospirosis that causes jaundice, a condition in which the skin and eyes may turn yellow. This happens when the body reacts strongly to the infection and the liver is affected, resulting in a buildup of bilirubin.
This condition is identified by its association with leptospirosis, an infection typically transmitted from animals. Due to its severe presentation, Weil's disease can lead to complications affecting multiple organ systems. Information about the full range of its effects on the body is limited in the available sources.
Information about symptoms is currently limited for this condition.
Information about causes is currently limited for this condition.
Preventive Strategies for Early and Late Complications of Leptospirosis
PHASE2
National Kidney and Transplant Institute, Philippines
RECRUITING
54 publications have been identified in PubMed for Weil's disease. Research spans Case Report / Case Series (58%), Epidemiology / Natural History (19%), and Review / Meta-Analysis (11%).
Research Type
Count
% of Total
Patient case studies
31
58%
Disease patterns and progression
10
19%
Research summaries
6
11%
Other research
2
4%
Clinical study results
2
4%
Testing and diagnosis research
1
2%
Laboratory research
1
2%
Recent Publications
Chatterjee D (2026). [PMID: 42082263](https://pubmed.ncbi.nlm.nih.gov/42082263/). *BMJ Case Rep*. [Case Report / Case Series]
Tokashiki T (2026). [PMID: 42156054](https://pubmed.ncbi.nlm.nih.gov/42156054/). *Brain Nerve*. [Review / Meta-Analysis]
After a year of controversial regulatory reversals, the FDA has accepted uniQure’s application for ifezuntirgene inilparvovec for priority review, with a May 1 action date. If approved, the therapy—also called AMT-130—would be the first disease-modifying treatment for Huntington’s disease.
Latest $1.5 Million Installment Reflects Continued Milestone Progress as DARE-LARC1 Advances in Preclinical Development · Company Exploring Potential Strategic Collaborations for DARE-IDDS Platform in Obesity, Diabetes and Other Large Chronic-Disease Markets Company Exploring Potential Strategic Collaborations for DARE-IDDS Platform in Obesity, Diabetes and Other Large Chronic-Disease Markets · SAN DIEGO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced receipt of an additional $1.5 million funding installment under its multi-year grant agreement in support of development of DARE-LARC1, an investigational long-acting reversible contraceptive based on Daré Bioscience's intelligent drug delivery system (DARE-IDDS) platform. Daré Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation Daré Bioscience advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Daré Bioscience is working to close critical gaps in care using science that serves her needs. Daré Bioscience believes the DARE-IDDS platform may have potential beyond women's health, including with GLP-1 analogs, anti-obesity medications, hormone therapies for areas such as diabetes, breast cancer, and infertility, and neurologic disease treatments such as for Parkinson’s disease, where long-term dosing and treatment burden are central challenges. In this press release, forward-looking statements include, but are not limited to, statements relating to: DARE-LARC1’s potential as a safe and effective long-acting reversible contraceptive product; continued development of DARE-LARC1; future submission of an IND application for DARE-LARC1; use of the funding installment received and potential for Daré Bioscience to receive additional funding under the grant agreement relating to DARE-LARC1; the potential capabilities of DARE-IDDS as part of a therapeutic product for humans, including storing and delivering discrete doses over periods rang
